Sign In
Buy RNA
$11.35
-0.110 (-0.96%)
At Close: Jul 31, 2026
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates
07:00pm, Thursday, 08'th May 2025
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.90 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to loss of $0.79 per share a year ago.
Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights
04:05pm, Thursday, 08'th May 2025
On track to deliver key regulatory updates for del-brax and topline data from dose escalation cohorts in the FORTITUDE™ trial in the second quarter Positive topline del-zota data further supports fi
Avidity Biosciences to Participate in Upcoming Investor Conference
09:00am, Tuesday, 06'th May 2025
SAN DIEGO , May 6, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Co
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 21'st Apr 2025
SAN DIEGO , April 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide
Del-desiran first-ever investigational treatment for DM1 to receive Orphan Drug designation in Japan SAN DIEGO , April 8, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmace
Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?
10:35am, Thursday, 03'rd Apr 2025
Avidity Biosciences (RNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength d
Avidity Biosciences to Participate in Upcoming Investor Conference
09:00am, Tuesday, 01'st Apr 2025
SAN DIEGO , April 1, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide
Del-brax FORTITUDE biomarker cohort designed for potential accelerated approval; plan to share regulatory update in Q2 2025 Regulatory alignment on global Phase 3 del-brax trial design and study initi
Del-brax FORTITUDE biomarker cohort designed for potential accelerated approval; plan to share regulatory update in Q2 2025 Regulatory alignment on global Phase 3 del-brax trial design and study initi
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 21'st Mar 2025
SAN DIEGO , March 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide
Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial
07:00am, Monday, 17'th Mar 2025
On track for year end 2025 BLA submission for accelerated approval of 5 mg/kg every six weeks of del-zota in DMD44 Consistent favorable safety and tolerability across del-zota dose cohorts Plan to p
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
04:05pm, Wednesday, 12'th Mar 2025
Aravindhan Veerapandiyan, MD, Associate Professor of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital and EXPLORE44 ® trial investigator, will present topline
SAN DIEGO , Feb. 28, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates
06:40pm, Thursday, 27'th Feb 2025
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.79 per share a year ago.
Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights
04:05pm, Thursday, 27'th Feb 2025
Building on success across its three clinical programs, Avidity is leading in rare neuromuscular diseases with a strong balance sheet to execute on a transformational 2025 M ajor milestones anticipate
